Clinical Effect Observation of Insulin Glargine U300 Combined With Oral Hypoglycemic Medicine on Type 2 Diabetes
Objective To explore the clinical effect of insulin glargine U300 combined with oral hypoglycemic medicine in the treatment of type 2 diabetes.Methods A total of 79 patients with type 2 diabetes who were admitted to Wuchuan People's Hospital,Guangdong Province from October 2021 to January 2023 were randomly divided into non-glycyrrhizin group(39 cases)and U300 group(40 cases).The non-glycine group was received oral hypoglycemic drug treatment.On top of this,the U300 group was received insulin glargine U300 treatment for 3 months.The changes in blood glucose and related indicators were compared between the two groups,and the improvement of insulin function related indicators was monitored to evaluate adverse reactions such as hypoglycemic reactions.Results After treatment,the blood glucose indicators and blood glucose fluctuation indicators in the U300 group were significantly lower than those in the non-glycine group,the differences were statistically significant(P<0.05).After treatment,the insulin function indicators in the U300 group were significantly better than those in the non-glargine group,and the fasting and 2-hour postprandial C-peptide levels were significantly higher than those in the non-glargine group,the differences were statistically significant(P<0.05).The incidence of hypoglycemic reactions(2.50%,1/40)and total incidence of adverse reactions(20.00%,8/40)in the U300 group were not statistically significant compared to the non-glyceride group(2.56%,1/39;17.95%,7/39)(P>0.05).Conclusion The increase of insulin glargine U300 treatment can better improve the blood glucose management effect of patients,and improve islet function,which is conducive to the stable control of blood glucose,and helps to improve the control effect of patients'condition.The application effect is safe and reliable.
万方数据
维普
